ABPI Logo
  • Developing medicines
    • Responding to COVID-19
    • Clinical trials and research
    • Building a thriving environment for medicine discovery
    • UK-EU Future Relationship
    • Life Sciences Industrial Strategy
    • ABPI Medical Representatives Exam
  • Accessing medicines
    • How medicines are priced in the UK
    • Working with the NHS
    • Supply chain
    • Antimicrobial resistance (AMR)
    • Vaccines
    • What is the NICE Methods Review?
    • Rare diseases: Facing three challenges
  • Our ethics
    • ABPI Code of Practice
    • Disclosure UK
    • Appropriate prescribing
    • Patient & public involvement
  • Member representation
    • Events
    • Full membership
    • Working with our members​
    • ABPI Members List
    • Membership benefits
  • Who We Are
  • Media
  • Publications
  • Facts and Figures
  • Contact Us
MY ABPI LOGIN
 
  • The Association of the British Pharmaceutical Industry
  • Accessing medicines
  • Vaccines
  • How are vaccines researched and developed?

How are vaccines researched and developed?

The UK has a longstanding reputation for cutting-edge research and development into vaccines. Investment by the pharmaceutical industry has resulted in a broad range of vaccines.

Today, the UK vaccinates against 15 diseases in its routine national immunisation program and against a further 5 diseases selectively to those most at risk or travellers.[1,2,3]

Vaccines

  • How are vaccines researched and developed?
  • What are the public health benefits of vaccination?
  • What are the economic and societal impacts of vaccines?
  • What does the future of vaccines look like?
  • Westminster Flu Day
1

Vaccine R&D can be a long and risky journey

Finding a new vaccine begins with understanding the structure of the virus or bacterium and how it causes the infection which are you are trying to prevent. Vaccines contain a harmless form of the bacteria or virus that causes the disease.

This means the bacteria or virus will be killed, greatly weakened, or broken down into small parts before being used to trigger an immune response in the person receiving the vaccine but without making them ill.

Carefully working out how to do this and selecting appropriate technologies happens in pre-clinical testing. It is then a case of thoroughly testing a vaccine through clinical trials to make sure it’s effective and safe to use.

Historically, developing a new vaccine has required:

icon
10 years of research for each successful vaccine
icon
12-18 months for first regulatory approval
icon
6% probability of market entry from preclinical
icon
£448 million cost of building a biological manufacturing site
icon
70% of production dedicated to quality control
icon
£374 million - £1.5 billion cost of development
icon
24 months to manufacture
2

But new technology is helping us speed that process up

Sustained investment and effective introduction of new technologies are essential to enable vaccine-preventable diseases to be controlled, eliminated and potentially eradicated.

By using advances in genetic sequencing for the viruses and bacteria that cause diseases, companies have managed to speed up vaccine R&D.

New technologies like artificial intelligence are helping to make the development of vaccines quicker.

Where similar diseases have appeared around the world, the research can increasingly be translated into research for vaccines against similar strains.

3

Pharmaceutical companies need to make rigorous decision about what they research

Developing vaccines takes deep scientific knowledge and expertise. Pharmaceutical companies need to make decisions about what research they’re going to invest in and generally look at four questions:

What value will it provided patients? They need to make sure the new vaccine establishes a new standard of care which has the potential to significantly extend and improve patient lives.

What value will be provided to health care systems? They aim to reduce the costs associated with hospitalisation and other costly complications of disease if not appropriately (or optimally) treated.

What is the unmet need? They need to make sure any new vaccine addresses a critically unmet medical need, where few or no treatments exists.

What is the R&D sustainability? What will continued investment in risky and capital-intensive R&D come up with, and is this a sufficiently important breakthrough?

4

Pharmaceutical companies are working in collaboration to develop new vaccines

When the global community works together, we can dramatically advance the development and delivery of vaccines. The pharmaceutical industry and the public sector, academia and non-governmental organisations have a long history of working together to research vaccines and to develop and manufacture them at scale.

The UK has a thriving ecosystem of public-private collaborations helping to push back the boundaries of science and find new vaccines.

ABPI member companies are working with the UK Vaccine Network on vaccines and technologies for infectious diseases with the potential to cause an epidemic.8

References and further links

Vaccine development stats

  • +10 years of R&D for each successful vaccine[1]
  • 12-18 months for first regulatory approval[2]
  • 24 months to manufacture[3]
  • 70% of production dedicated to quality control1
  • 6% probability of market entry from preclinical1
  • £374 million-£1.5 billion GBP cost of development[4]
  • £485 million cost of building a biological manufacturing site1

Page references

[1] IFPMA. Innovation for a healthier world 2015. Accessible at: https://www.ifpma.org/resource-centre/innovation-for-a-healthier-world-how-the-research-based-vaccine-manufacturers-are-contributing-to-the-decade-of-vaccines-action-plan/ Last accessed April 2020. Values converted from USD at prevailing exchange rate on 8/4/20

[2] Vaccines Europe. The EU vaccine industry in Figures. 2015. Available at: https://www.vaccineseurope.eu/about-vaccines/vaccines-europe-in-figures/ Last accessed June 2018

[3] Plotkin S et al. The complexity of vaccine manufacturing - an overview. Vaccine 2017;35;4064-4071

[4] O’Neill J. Vaccines and alternative approaches; reducing our dependence on antimicrobials. February 2016. Available at: https://amr-review.org/sites/default/files/Vaccines%20and%20alternatives_v4_LR.pdf Last accessed June 2018

ABPI

The Association of the British Pharmaceutical Industry is a company limited by guarantee registered in England and Wales 
(registered number 09826787) and its registered office is at 7th Floor Southside,105 Victoria Street, London, SW1E 6QT.
Telephone +44 (0) 207 9303477

© ABPI 2021
  • Twitter Logo
  • LinkedIn
  • YouTube Logo

Devolved Nations

  • Cymru Wales
  • Northern Ireland
  • Scotland

Quick Links

  • ABPI Exam
  • Disclosure UK
  • Frequently Asked Questions
  • Careers
  • Schools
  • Acronym buster

Website Info

  • Terms and conditions
  • Accessibility
  • Cookie Policy

Prescription Medicines Code of Practice Authority (PMCPA)

The Prescription Medicines Code of Practice Authority (PMCPA) was established by The Association of the British Pharmaceutical Industry to operate the ABPI Code of Practice for the Pharmaceutical Industry independently of the ABPI. The PMCPA is a division of ABPI which is a company registered in England and Wales (registered number 09826787) with its registered office at 7th Floor, Southside, 105 Victoria Street, London SW1E 6QT.

Office of Health Economics (OHE)

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 7th Floor Southside, 105 Victoria Street, London, SW1E 6QT. OHE provides independent research, advisory and consultancy services on policy implications and economic issues within the pharmaceutical, health care and biotechnology sectors.